

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage of Sandoz Carbamazepine CR 200 mg Sustained-Release Tablet (DIN 02261839) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **January 18, 2016:**

CARBAMAZEPINE

200 MG ORAL SUSTAINED-RELEASE TABLET

00002241882	MYLAN-CARBAMAZEPINE CR	MYP	\$ 0.0930
00002231543	PMS-CARBAMAZEPINE-CR	PMS	\$ 0.0930
00002261839	SANDOZ CARBAMAZEPINE CR	SDZ	\$ 0.0930
00000773611	TEGRETOL CR	NOV	\$ 0.4063

Alberta Blue Cross has been advised by Hospira Healthcare Corporation that the shortage of Deferoxamine Mesylate 2 g/Vial for Injection (DIN 02247022) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping **January 18, 2016:**

DEFEROXAMINE MESYLATE

2 G / VIAL INJECTION

00002247022	DEFEROXAMINE MESYLATE	HSP	\$ 20.4027
00001981250	DESFERAL	NOV	\$ 57.5300

Alberta Blue Cross has been advised by Apotex Inc., Teva Canada Limited and Pharmascience Inc. that the shortages of Apo-Desmopressin 0.2 mg Tablet (DIN 02284049), Novo-Desmopressin 0.2 mg Tablet (DIN 02287749) and pms-Desmopressin 0.2 mg Tablet (DIN 02304376) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **January 22, 2016:**

DESMOPRESSIN ACETATE

0.2 MG ORAL TABLET

00002284049	APO-DESMOPRESSIN	APX	\$ 0.6608
00002287749	NOVO-DESMOPRESSIN	TEV	\$ 0.6608
00002304376	PMS-DESMOPRESSIN	PMS	\$ 0.6608
00000824143	DDVAP	FEI	\$ 2.6670

... continued from previous page

Alberta Blue Cross has been advised by Apotex Inc., Mylan Pharmaceuticals ULC, Sanis Health Inc., Pharmascience Inc. and Teva Canada Limited that the shortages of Apo-Naproxen EC 500 mg Enteric-Coated Tablet (DIN 02246701), Mylan-Naproxen EC 500 mg Enteric-Coated Tablet (DIN 02241024), Naproxen EC 500 mg Enteric-Coated Tablet (DIN 02350807), pms-Naproxen EC 500 mg Enteric-Coated Tablet (DIN 02294710) and Teva-Naprox EC 500 mg Enteric-Coated Tablet (DIN 02243314), have been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **January 22, 2016**:

NAPROXEN

500 MG ORAL ENTERIC-COATED TABLET

00002246701	APO-NAPROXEN EC	APX	\$ 0.2110	\$ 0.2110
00002241024	MYLAN-NAPROXEN EC	MYP	\$ 0.2110	\$ 0.2110
00002350807	NAPROXEN EC	SNS	\$ 0.2110	\$ 0.2110
00002294710	PMS-NAPROXEN EC	PMS	\$ 0.2110	\$ 0.2110
00002243314	TEVA-NAPROX EC	TEV	\$ 0.2110	\$ 0.2110
00002162423	NAPROSYN E	HLR	\$ 0.2110	\$ 1.0537

MAC pricing has been applied based on the LCA price for 1 x 500 mg oral tablet.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)



*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ABC 82320.571 2015/12